Market Snapshot
S&P Futures
3,809.5
Dow Futures
30,868
Nasdaq Futures
11,633.25
Arvinas, Inc. (ARVN) stock declined over -3.55% intraday to trade at $42.09 a share on NASDAQ. The stock opened with a loss of -0.73% at $42.96 and touched an intraday high of $43.895, falling -3.55% against the last close of $43.64. The stock went to a low of $41.455 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-30 | $42.96 | $43.895 | $41.455 | $42.09 | 383,608 |
2022-06-29 | $42.4 | $43.88 | $40.86 | $43.64 | 309,900 |
2022-06-28 | $45.7 | $45.7 | $41.79 | $42.68 | 354,900 |
2022-06-27 | $45.99 | $46.05 | $43.02 | $45.46 | 583,200 |
2022-06-24 | $43.08 | $46.22 | $42.34 | $45.8 | 1,185,000 |
2022-06-23 | $39.71 | $42.63 | $39.71 | $42.42 | 381,000 |
2022-06-22 | $38.39 | $41.26 | $38.39 | $39.49 | 266,400 |
2022-06-21 | $38.71 | $40.91 | $38.68 | $38.89 | 324,600 |
2022-06-17 | $37.51 | $39.9 | $37.46 | $38.35 | 555,200 |
2022-06-16 | $37.03 | $37.32 | $35.14 | $36.79 | 353,200 |
Employees-
Beta1.96
Sales or Revenue46.7 Million
5Y Sales Change47.60%
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryPharmaceuticals
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
Arvinas, Inc. (NASDAQ: ARVN) stock price is $42.09 as of the last check on Thursday, June 30. During the trading session, ARVN stock reached the peak price of $43.895 while $41.455 was the lowest point it dropped to.
The NASDAQ listed ARVN is part of Pharmaceuticals industry that operates in the broader Health Care sector. Arvinas, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Dr. Craig M. Crews
Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
Dr. Robert Kleinfield
Chief Devel. Officer
Dr. John G. Houston Ph.D.
CEO, Pres & Director
Mr. Sean A. Cassidy CPA, CPA, M.B.A.
CFO & Treasurer
ARVN stock traded closed the last session at $42.09, which is $-1.55 or -3.55% lower than its previous close of $43.64. ARVN's current trading price is 20.60% lower than its 52-week high of $108.46 where as its distance from 52-week low of 34.90% is -61.19%.
Number of ARVN employees currently stands at -. ARVN operates from 5 Science Park, 395 Winchester Avenue, New Haven, CT 06511, United States.
Official Webiste of $ARVN is: https://www.arvinas.com
ARVN could be contacted at ARVN operates from 5 Science Park, 395 Winchester Avenue, New Haven, CT 06511, United States, or at phone #203 535 1456 and can also be accessed through its website.
ARVN stock volume for the day was 402,670 shares while in the previous session number of ARVN shares traded was 383,608 . The average number of ARVN shares traded daily for last 3 months was 494.65 Thousands.
The percentage change in ARVN stock occurred in the recent session was -3.55% while the dollar amount for the price change in ARVN stock was $-1.55.
In the recent session, the day high for ARVN stock was $43.895 while the low for ARVN stock touched on the day was $41.455.
The market value of ARVN currently stands at 2.07 Billion with its latest stock price at $42.09 and 53 Million of its shares outstanding.